Autoimmune Epilepsy

Case Study 1

17-year-old female with motor abnormalities and neuropsychiatric symptoms
Symptoms improved with antibiotic treatment

Presenting Symptoms: Seizures, obsessive/compulsive symptoms, poor concentration, emotional lability, aggression, sensory and motor abnormalities, gradually worsening over several days.

Course of Illness: Relapsing and remitting course

Diagnosis: Epilepsy; Disorder of immune mechanism; Personal history of other diseases of the digestive system; Methylenetetrahydrofolate reductase deficiency; Fatigue; Sleep problems.

Medical History: Known immune deficiency with multiple previous infections from organisms including Borrelia, Bartonella, C. Albicans, C. pneumoniae, HHV6, Staph, Strep, Mycoplasma pneumonia.

Family History: Positive for autoimmune disorders and allergies.

Pre-Treatment Cunningham Panel™ results: Elevated anti-Dopamine D1 autoantibodies 4,000 (normal range 500-2,000); normal anti-Dopamine D2L autoantibodies 4,000 (normal range 2,000-8,000); elevated anti-Lysoganglioside GM1 autoantibodies 640 (normal range 80-320); elevated anti-Tubulin autoantibodies 2,000 (normal range 250-1,000); elevated CaMKII 165 (normal range 53-130).

Treatment: Antibiotics, with additional nutraceuticals.

Status: Neurological symptoms significantly improved following treatment.

Post-Treatment Cunningham Panel™ results: Normal anti-Dopamine D1 autoantibodies 1,000 (normal range 500-2,000); normal anti-Dopamine D2L autoantibodies 2,000 (normal range 2,000-8,000); normal anti-Lysoganglioside GM1 160 (normal range 80-320); borderline anti-Tubulin autoantibodies 1,000 (normal range 250-1,000); elevated CaMKII 146 (normal range 53-130).


Anti-Dopamine D1 Receptor Autoantibodies — 4,000 (elevated)

Anti-Dopamine D2L Receptor Autoantibodies — 4,000 (normal)

Anti-Lysoganglioside GM1 Autoantibodies — 640 (elevated)

Anti-Tubulin Autoantibodies — 2,000 (elevated)

CaMKinase II — 165 (elevated)


Anti-Dopamine D1 — 1,000 (normal)

Anti-Dopamine D2L — 2,000 (normal)

Anti-Lysoganglioside GM1 — 160 (normal)

Anti-Tubulin — 1,000 (borderline)

CaMKinase II — 146 (elevated)

17-year-old girl with a history of immune deficiency and recurrent infections, presenting with multiple neurologic and psychiatric symptoms worsening over several days. Pre-treatment Cunningham Panel™ showed elevations in antineuronal antibodies and CaMKII enzyme indicating likely active infection. Responded well to treatment with antimicrobials and supplements.
Patient Symptomatic

Patient symptoms pre-treatment consistent with elevated autoantibodies to Dopamine D1 (anxiety, sleep problems, emotional lability, aggression) and elevated anti-Tubulin antibodies (obsessive-compulsive symptoms, poor concentration), and elevated CaMKII (seizures, sensory and motor abnormalities).

Cunningham Panel pretest for autoimmune epilepsy
Symptom Resolution

Patient and parent estimate approximately 90% resolution of neurologic and psychiatric symptoms after treatment with antibiotics.

Cunningham Panel posttest for autoimmune epilepsy
Ordering the Panel is Easy!

The Cunningham Panel™ of tests requires a clinician order before we can receive and process any specimen. Moleculera Labs can accept authorized clinician test orders from all 50 states in the United States and other countries. (New York patients must have their blood collected outside the State of New York.)

Cunningham Panel physician portal

Set-up an account

In our secure online portal and submit your order.

Cunningham Panel Ordering Process and Testing Costs


About the Ordering Process and Testing Costs

Understanding Test Results

We provide ordering clinicians with personalized clinical support for their patient test results.

Fill out the form below to schedule your appointment. Note: This service is open to individual clinicians and group practices only.